Growth of the 340B Program Accelerates in 2020
In August 2020, IQVIA published results of an analysis1 of the size and growth of the 340B Drug Discount Program ("340B Program"), showing it had grown 17.1% year-on-year in 2019 and accounted for $67.4B of pharma sales (dollarized using WAC pricing). READ MORE
Report Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!